Skip to main content

Table 4 Analysis for OS of patients according to hormone receptor status

From: Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases

 

HR positive patients

HR negative patients

 

Univariate

Multivariate

Univariate

Multivariate

Variables

Hazard ratio (95% CI)

P -value

Hazard ratio (95% CI)

P -value

Hazard ratio (95% CI)

P -value

Hazard ratio (95% CI)

P -value

Age < 40 yr

0.85

(0.60–1.19)

0.344

-

-

0.75

(0.47–1.21)

0.237

-

-

Postmenopausal state

1.26

0.81–1.94)

0.302

-

-

-

-

-

-

HER2 positive

1.66

(1.15–2.40)

0.007

1.54

(1.06–2.23)

0.022

0.67

(0.43–1.06)

0.088

-

-

DFI* > 2 yr

0.76

(0.54–1.07)

0.12

-

-

0.61

(0.38–0.98)

0.040

0.59

(0.36–0.97)

0.036

Initial stage IV

0.76

(0.49–1.19)

0.232

-

-

0.96

(0.58–1.59)

0.882

-

-

Sum of metastasis sites ≥ 3

1.32

(0.94–1.83)

0.105

-

-

1.83

(1.13–2.97)

0.014

1.70

(1.04–2.78)

0.034

Visceral metastasis

1.78

(1.28–2.48)

0.001

1.7

(1.22–2.38)

0.002

-

-

-

-

BP** use

0.67

(0.42–1.19)

0.111

-

-

0.56

(0.34–0.91)

0.019

0.50

(0.30–0.83)

0.007

  1. Abbreviations: *, disease free interval; **, bisphosphonate.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us